Somatostatin Receptor
Showing 1 - 25 of 7,331
Nasopharyngeal Cancer, Epstein-Barr Virus Related Carcinoma Trial in Singapore (FDG-PET, Galium-68 DOTATATE)
Recruiting
- Nasopharyngeal Cancer
- Epstein-Barr Virus Related Carcinoma
- FDG-PET
- Galium-68 DOTATATE
-
Singapore, SingaporeNational Cancer Centre Singapore
Oct 13, 2022
Neuroendocrine Tumors Trial in Beijing (Lutetium[177Lu] Oxodotreotide Injection)
Not yet recruiting
- Neuroendocrine Tumors
- Lutetium[177Lu] Oxodotreotide Injection
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
May 30, 2023
Breast Cancer Stage IV Trial in Irvine (Gallium-68)
Recruiting
- Breast Cancer Stage IV
-
Irvine, CaliforniaHoag Memorial Hospital Presbyterian
May 26, 2023
Lutathera® in Somatostatin Receptor Positive
Recruiting
- Somatostatin Receptor-positive GEP-NET
- Lutathera
-
Seongnam Si, Gyeonggi Do, Korea, Republic of
- +4 more
Jun 29, 2022
LUTATHERA Injection General Use Result Survey
Recruiting
- Somatostatin Receptor-positive Neuroendocrine Tumor
- LUTATHERA
-
Kashiwa, Chiba, Japan
- +6 more
Apr 25, 2023
Neuroendocrine Tumors Trial in Edmonton (68Ga-HA-DOTATATE)
Recruiting
- Neuroendocrine Tumors
-
Edmonton, Alberta, CanadaUniversity of Alberta
Apr 11, 2022
Neuroendocrine Tumors, Carcinoid Tumor, Pulmonary Carcinoid Tumor Trial in Vancouver (177Lu-DOTATOC)
Not yet recruiting
- Neuroendocrine Tumors
- +6 more
-
Vancouver, British Columbia, CanadaBC Cancer
Aug 19, 2022
68-Ga DOTATATE PET/MRI in Diagnosis and Management of
Recruiting
- CNS Tumors
- +6 more
- Ga68-DOTATATE-PET/MRI
-
New York, New YorkWeill Cornell Medicine
Sep 20, 2022
Somatostatin Receptors and GH Receptor Expression on Bone of
Completed
- Evaluation of the Expression of Somatostatin Receptors and GH Receptor on Bone of Acromegalic Patients
- Trans-sphenoidal surgery
-
Roma, ItalyFondazione Policlinnico Gemelli IRCCS
Apr 6, 2023
Neuroendocrine Carcinoma Trial in London (Lu-DOTA-TATE)
Active, not recruiting
- Neuroendocrine Carcinoma
- Lu-DOTA-TATE
-
London, Ontario, CanadaLondon Health Sciences Centre
Apr 5, 2022
Neuroendocrine Tumors Trial in Portland (Cabozantinib, Lu-177)
Not yet recruiting
- Neuroendocrine Tumors
-
Portland, OregonProvidence Portland Cancer Institute - Franz Clinic
Feb 10, 2022
Hepatocellular Carcinoma Trial in Birmingham ([68Ga]DOTATATE-PET/MRI)
Completed
- Hepatocellular Carcinoma
-
Birmingham, AlabamaUniversity of Alabama at Birmingham Medical Center
Dec 16, 2022
Neuroendocrine Neoplasia's (NENs), Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) Trial in Basel (161Tb-DOTA-LM3,
Not yet recruiting
- Neuroendocrine Neoplasia's (NENs)
- Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
-
Basel, SwitzerlandDivision of Nuclear Medicine, University Hospital Basel
Apr 27, 2022
Neuroendocrine Tumors, Somatostatin Receptor-positive Neuroendocrine Tumor Trial in Madison (Single Photon Emission Computed
Not yet recruiting
- Neuroendocrine Tumors
- Somatostatin Receptor-positive Neuroendocrine Tumor
- Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)
- +3 more
-
Madison, WisconsinUniversity of Wisconsin - Madison
Nov 2, 2023
Neuroendocrine Tumors, Meningioma, Neuroblastoma Trial in Iowa City (radiation, diagnostic test, drug)
Active, not recruiting
- Neuroendocrine Tumors
- +3 more
- 90Y-DOTA tyr3-Octreotide
- +2 more
-
Iowa City, IowaUniversity of Iowa Hospitals and Clinics
Oct 6, 2022
SCLC,Extensive Stage Trial in Omaha (RYZ101 Dose Level 1, RYZ101 Dose Level 2, RYZ101 Dose Level 3)
Recruiting
- SCLC,Extensive Stage
- RYZ101 Dose Level 1
- +6 more
-
Omaha, NebraskaNebraska Cancer Specialists
Nov 18, 2022
Advanced Gastroenteropancreatic Neuroendocrine Tumor Trial (Lutetium (177Lu) Oxodotreotide Injection;long-acting Octreotide,
Not yet recruiting
- Advanced Gastroenteropancreatic Neuroendocrine Tumor
- Lutetium (177Lu) Oxodotreotide Injection;long-acting Octreotide
- long-acting Octreotide.
- (no location specified)
May 22, 2023
Advanced Lung Carcinoid Tumor, Functioning Lung Carcinoid Tumor, Locally Advanced Lung Neuroendocrine Tumor Trial in Boston,
Recruiting
- Advanced Lung Carcinoid Tumor
- +11 more
- Everolimus
- Lutetium Lu 177 Dotatate
-
Boston, Massachusetts
- +1 more
Jul 19, 2022
Small Cell Lung Cancer and Breast Cancer Trial in Worldwide (Satoreotide tetraxetan, Satoreotide trizoxetan)
Terminated
- Small Cell Lung Cancer and Breast Cancer
- Satoreotide tetraxetan
- Satoreotide trizoxetan
-
Houston, Texas
- +7 more
Aug 22, 2022
Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor Grade 1 Trial ([203Pb]VMT-a-NET, SPECT/CT)
Enrolling by invitation
- Neuroendocrine Tumor Grade 2
- Neuroendocrine Tumor Grade 1
- [203Pb]VMT-α-NET
- SPECT/CT
-
Iowa City, IowaThe University of Iowa
Dec 9, 2022
Neuroendocrine Tumors, Lung Neuroendocrine Tumor, Thymus Tumors Trial in France, Italy, Spain (177Lu-edotreotide, Everolimus)
Not yet recruiting
- Neuroendocrine Tumors
- +2 more
-
Bourdeaux, France
- +24 more
Jun 23, 2023
Myocarditis Trial in Vandoeuvre/les/nancy (DOTATOC-68Ga PET initial, DOTATOC-68Ga PET at 6 months, blood sample)
Recruiting
- Myocarditis
- DOTATOC-68Ga PET initial
- +2 more
-
Vandoeuvre/les/nancy, FranceVéronique ROCH
Aug 3, 2021
Neuroendocrine Tumors Trial in Houston (AlphaMedix)
Recruiting
- Neuroendocrine Tumors
-
Houston, TexasExcel Diagnostics and Nuclear Oncology Center
Jan 5, 2022
Neuroendocrine Tumors Trial in Leuven (Al18F-NOTA-octreotide, PET/CT, PET/MR)
Completed
- Neuroendocrine Tumors
- Al18F-NOTA-octreotide
- +2 more
-
Leuven, BelgiumUniversitaire Ziekenhuizen Leuven
Feb 16, 2022